CHAD WHYTE: Open Payments
NPI 1427222959 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$96,723 in 309 payments from 30 companies in 2025. Trend: 2023 $88,776 · 2024 $48,432 · 2025 $96,723
Speaker / faculty: $53,325Honoraria: $35,152Food & beverage: $4,752Consulting: $2,525Travel & lodging: $968
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 71 | $44,928 |
| Axsome Therapeutics, Inc. | 34 | $25,726 |
| Lundbeck LLC | 30 | $12,557 |
| PFIZER INC. | 23 | $11,266 |
| Teva Pharmaceuticals USA, Inc. | 34 | $324 |
| Novartis Pharmaceuticals Corporation | 20 | $262 |
| UCB, Inc. | 29 | $248 |
| Neurocrine BioSciences, Inc. | 13 | $193 |
| Merz Pharmaceuticals, LLC | 8 | $147 |
| ARGENX US, INC. | 5 | $129 |
Products named: QULIPTA, Symbravo, VYEPTI, NURTEC ODT, UBRELVY, AUSTEDO XR, KESIMPTA, INGREZZA.
Industry payments across NE — which companies pay providers there.
